We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OGT to Exhibit its Tailored Biomarker Discovery Solutions at Companion Diagnostics 2011 in Frankfurt
Product News

OGT to Exhibit its Tailored Biomarker Discovery Solutions at Companion Diagnostics 2011 in Frankfurt

OGT to Exhibit its Tailored Biomarker Discovery Solutions at Companion Diagnostics 2011 in Frankfurt
Product News

OGT to Exhibit its Tailored Biomarker Discovery Solutions at Companion Diagnostics 2011 in Frankfurt


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "OGT to Exhibit its Tailored Biomarker Discovery Solutions at Companion Diagnostics 2011 in Frankfurt"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be attending this year’s Companion Diagnostics Summit Europe in Frankfurt (22nd to 24th March).

Will Colón (Business Development Director, Biomarker Discovery) and Graham Speight (Head of Genomic Biomarkers) will be present to talk with delegates about OGT’s tailored biomarker discovery solutions.

The aim of the meeting is to discuss the best way to convert biomarker research into more accurate diagnostic methods and safer and more successful drug treatment strategies.

OGT has already had significant success developing reliable and accurate solutions as part of its in-house biomarker discovery programmes, targeting diseases such as prostate cancer, systemic lupus erythematosus (SLE) and colorectal cancer.
Advertisement